<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1662-4548</issn>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32116499</article-id>
<article-id pub-id-type="pmc">7012787</article-id>
<article-id pub-id-type="doi">10.3389/fnins.2020.00042</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Abramzon</surname>
<given-names>Yevgeniya A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fratta</surname>
<given-names>Pietro</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/507752/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Traynor</surname>
<given-names>Bryan J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chia</surname>
<given-names>Ruth</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/819981/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH</institution>, <addr-line>Bethesda, MD</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Neurology, Brain Science Institute, Johns Hopkins University</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Francesca Luisa Conforti, University of Calabria, Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Paola Mandich, University of Genoa, Italy; David G. Ashbrook, The University of Tennessee Health Science Center (UTHSC), United States</p>
</fn>
<corresp id="c001">*Correspondence: Yevgeniya A. Abramzon, <email>yevgeniya.abramzon@nih.gov</email></corresp>
<fn fn-type="other" id="fn004">
<p>This article was submitted to Neurogenomics, a section of the journal Frontiers in Neuroscience</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>14</volume>
<elocation-id>42</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Abramzon, Fratta, Traynor and Chia.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Abramzon, Fratta, Traynor and Chia</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two diseases that form a broad neurodegenerative continuum. Considerable effort has been made to unravel the genetics of these disorders, and, based on this work, it is now clear that ALS and FTD have a significant genetic overlap. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players in these neurological disorders. Discoveries of these genes have implicated autophagy, RNA regulation, and vesicle and inclusion formation as the central pathways involved in neurodegeneration. Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight the genetic and pathological overlaps.</p>
</abstract>
<kwd-group>
<kwd>amyotrophic lateral sclerosis</kwd>
<kwd>frontotemporal dementia</kwd>
<kwd>neurological disorders</kwd>
<kwd>neurodegeneration</kwd>
<kwd>overlapping genetics</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Institute on Aging<named-content content-type="fundref-id">10.13039/100000049</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn002">National Institute of Neurological Disorders and Stroke<named-content content-type="fundref-id">10.13039/100000065</named-content></funding-source>
</award-group>
<award-group>
<funding-source id="cn003">UCL Institute of Neurology, University College London<named-content content-type="fundref-id">10.13039/501100000845</named-content></funding-source>
</award-group>
</funding-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="127"></ref-count>
<page-count count="10"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a fatal neurological disorder affecting motor neurons located in the frontal cortex, brainstem, and spinal cord (<xref ref-type="bibr" rid="B28">Cleveland and Rothstein, 2001</xref>). The disease typically begins as muscle weakness in a limb, or occasionally with changes in voice or difficulty swallowing, which progresses to generalized weakness and paralysis of respiratory muscles leading to death due to respiratory failure. Approximately 10% of all ALS cases have a family history of the disease, while the remaining 90% are sporadic. The incidence of ALS is estimated to be 2.1 new cases per 100,000 population per year (<xref ref-type="bibr" rid="B25">Chio et al., 2013</xref>), and approximately 6,000 people are newly diagnosed with ALS each year in the United States alone. The number of ALS cases around the world is increasing due to the aging of the global population (<xref ref-type="bibr" rid="B8">Arthur et al., 2016</xref>). There are currently no effective treatments for ALS, except for edaravone, which reduces the decline in daily functioning, and riluzole, which prolongs patients’ survival by a few months (<xref ref-type="bibr" rid="B75">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="B94">Rothstein, 2017</xref>).</p>
<p>Frontotemporal degeneration (FTD) is one of the most common types of dementia in people under 65. FTD may be divided into three primary subtypes, namely behavioral variant, semantic dementia, and progressive non-fluent aphasia. Among these subtypes, behavioral variant FTD is the most commonly observed type of dementia associated with motor neuron disorders (<xref ref-type="bibr" rid="B15">Bird et al., 1999</xref>). The incidence of FTD is approximately 4.0 new cases per 100,000 population per year, with 40% of cases being familial (<xref ref-type="bibr" rid="B90">Ratnavalli et al., 2002</xref>). Similar to ALS and other neurological disorders, there is no effective treatment for FTD (<xref ref-type="bibr" rid="B108">Tsai and Boxer, 2014</xref>).</p>
<p>It is now recognized that ALS and FTD are two diseases that form a broad neurodegenerative continuum. One of the earliest hints of this overlap came from the clinical observation that both disorders can be present within the same family or even within the same individual. Cross-sectional studies performed over the last decade estimate that up to 50% of ALS patients develop cognitive impairment associated with FTD. Similarly, up to 30% of FTD patients develop motor dysfunction (<xref ref-type="bibr" rid="B22">Burrell et al., 2011</xref>).</p>
<p>Considerable progress has been made in unraveling the genetics of ALS and FTD, and it is now clear that the genetics of these two neurodegenerative conditions overlap significantly. TARDBP, SQSTM1, VCP, FUS, TBK1, CHCHD10, and most importantly C9orf72, are the critical genetic players, and their discoveries have implicated autophagy, RNA processing, and vesicle and inclusion formation as the central pathways involved in these forms of neurodegeneration.</p>
<p>Here we provide a summary of the significant genes identified in these two intrinsically linked neurodegenerative diseases and highlight where cross-talk exists. We describe the genes in the order of their relevance to ALS/FTD overlap, ranging from genes that have been demonstrated to cause both clinically and neuropathologically confirmed ALS and FTD to genes where the cognitive or motor symptoms are reported in the literature but pathological confirmation in not yet available.</p>
<p>The genes described in this review, clinical phenotypes and pathways associated with them are summarized in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Key genes identified in ALS and FTD.</p>
</caption>
<table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
<thead>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Locus</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Neurological phenotypes</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Pathway</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>Main localization</bold>
</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FUS</td>
<td align="left" colspan="1" rowspan="1" valign="top">16p11.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALS, FTD, ALS (juvenile with BIs) ET, MND (lower), bvFTD?, PD?</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleocytoplasmic transport/splicing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TDP-43</td>
<td align="left" colspan="1" rowspan="1" valign="top">1p36.22</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALS, FTD, ALS (flail arm variant), SNGP and chorea, MND</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleocytoplasmic transport/splicing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CHCHD10</td>
<td align="left" colspan="1" rowspan="1" valign="top">22q11.23</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALS, ALS/FTD, Mitochondrial myopathy (autosomal dominant)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mitochondrial dysfunction/Synaptic integrity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mitochondrion, nucleus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">C9orf72</td>
<td align="left" colspan="1" rowspan="1" valign="top">9p21.2</td>
<td align="left" colspan="1" rowspan="1" valign="top">AD, ALS, FTD, ALS/FTD, BD, PD, Schizophrenia</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleocytoplasmic transport/splicing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Extracellular, nucleus, endosome, lysosome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">UBQLN2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Xp11.21</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALS, FTD, Neurodegeneration, X-linked</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autophagy/Proteasome</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cytosol, plasma membrane, nucleus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TBK1</td>
<td align="left" colspan="1" rowspan="1" valign="top">12q14.1</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALS, ALS/FTD, AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autophagy/inflammation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleus, cytosol, endosome, mitochondrion</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VCP</td>
<td align="left" colspan="1" rowspan="1" valign="top">9p13.3</td>
<td align="left" colspan="1" rowspan="1" valign="top">IBMPFD, ALS, IBMPFD and ALS, CMT2, HSP DMRV, Scapuloperoneal muscular dystrophy and dropped head fibers, AD?, Autism?</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autophagy/Mitochondrial function</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleus, endoplasmic reticulum, cytosol, extracellular, lysosome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SQSTM1</td>
<td align="left" colspan="1" rowspan="1" valign="top">5q35</td>
<td align="left" colspan="1" rowspan="1" valign="top">PDB, ALS, FTD, AD, early onset ALS/FTD, NADGP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autophagy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleus, cytosol, lysosome, endoplasmic reticulum, endosome</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib>
<italic>IBMPFD, inclusion body myopathy with Paget disease and frontotemporal dementia; AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; HSP, hereditary spastic paraplegia; CMT2, charcot-marie-tooth disease, type 2; PDB, paget’s disease of bone; PD, Parkinson disease; BD, bipolar disorder; MND, motor neuron disease; ET, essential tremor; Bis, basophilic inclusions; DMRV-Myopathy, rimmed vacuolar; NADGP, neurodegeneration, childhood onset with ataxia, dystonia and gaze palsy; SNGP, supranuclear gaze palsy.</italic>
</attrib>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S2">
<title>Chromosome 9 Open Reading Frame 72 (C9Orf72)</title>
<p>In 2011, a hexanucleotide repeat expansion within the C9orf72 gene located on chromosome 9p21 was identified as a significant genetic cause of both ALS and FTD (<xref ref-type="bibr" rid="B33">DeJesus-Hernandez et al., 2011</xref>; <xref ref-type="bibr" rid="B92">Renton et al., 2011</xref>). This repeat expansion is the most common genetic cause of ALS, FTD, and ALS/FTD responsible for ∼11% of all ALS and ∼13% of all FTD cases. This discovery demonstrated that there is a more considerable genetic overlap between ALS and FTD than had been previously estimated. The majority of C9orf72-related FTD cases manifest behavioral symptoms with a much smaller percentage presenting with semantic dementia or with progressive non-fluent aphasia. C9orf72 repeat expansions have also been implicated as rare causes of other neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, progressive supranuclear palsy, ataxia, corticobasal syndrome, Huntington disease-like syndrome, and Creutzfeldt–Jakob disease (<xref ref-type="bibr" rid="B13">Beck et al., 2013</xref>; <xref ref-type="bibr" rid="B50">Hensman Moss et al., 2014</xref>; <xref ref-type="bibr" rid="B35">Devenney et al., 2018</xref>).</p>
<p>Several mechanisms have been proposed to explain how C9orf72 expansion causes neurological disease. These include (<xref ref-type="bibr" rid="B28">Cleveland and Rothstein, 2001</xref>) haploinsufficiency of C9orf72 protein (<xref ref-type="bibr" rid="B33">DeJesus-Hernandez et al., 2011</xref>; <xref ref-type="bibr" rid="B92">Renton et al., 2011</xref>; <xref ref-type="bibr" rid="B25">Chio et al., 2013</xref>; <xref ref-type="bibr" rid="B100">Shi et al., 2018</xref>; <xref ref-type="bibr" rid="B99">Shao et al., 2019</xref>) RNA toxicity due to accumulation of RNA containing the GGGGCC repeat in the brain and spinal cord (<xref ref-type="bibr" rid="B33">DeJesus-Hernandez et al., 2011</xref>; <xref ref-type="bibr" rid="B92">Renton et al., 2011</xref>; <xref ref-type="bibr" rid="B8">Arthur et al., 2016</xref>; <xref ref-type="bibr" rid="B9">Arzberger et al., 2018</xref>) dipeptide repeat (DPR) protein toxicity arising from repeat-associated non-AUG translation occurring off the expansion (<xref ref-type="bibr" rid="B75">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="B74">May et al., 2014</xref>; <xref ref-type="bibr" rid="B44">Freibaum and Taylor, 2017</xref>) disruption of the nucleocytoplasmic transport (<xref ref-type="bibr" rid="B43">Freibaum et al., 2015</xref>; <xref ref-type="bibr" rid="B59">Jovicic et al., 2015</xref>; <xref ref-type="bibr" rid="B125">Zhang et al., 2015</xref>). Although the data for each of these mechanisms are compelling, it is not yet clear which of them plays the dominant role in determining neurodegeneration. The possibility of multiple mechanisms, operating in either unison or sequentially to bring about neuronal death, cannot be discounted.</p>
<p>Various mouse models have been created to elucidate the pathogenic mechanism underlying C9orf72 neurodegeneration. Though informative, these models have failed to resolve the exact mechanism, as the available information bolsters all four modes of neurodegeneration. For example, mice lacking C9orf72 in neurons and glial cells did not display motor neuron degeneration or defects in motor function associated with ALS (<xref ref-type="bibr" rid="B64">Koppers et al., 2015</xref>). BAC transgenic mice with expanded human C9orf72 hexanucleotide repeat that ranged between 100 and 1000 repeats developed RNA foci and dipeptide repeat proteins throughout the nervous system. However, there was no evidence of neurodegeneration or functional deficits (<xref ref-type="bibr" rid="B84">O’Rourke et al., 2015</xref>; <xref ref-type="bibr" rid="B88">Peters et al., 2015</xref>). Mice with more than 450 GGGGCC repeats have mild hippocampal neuronal loss and display signs of age-dependent anxiety and impaired cognitive functioning (<xref ref-type="bibr" rid="B57">Jiang et al., 2016</xref>).</p>
<p>More recent mouse models showed that that loss of C9orf72 in a gain-of-function C9ALS/FTD mouse model aggravates motor behavior deficits in a dose-dependent manner (<xref ref-type="bibr" rid="B99">Shao et al., 2019</xref>). Transgenic GFP-PR28 mice expressing arginine-rich poly(PR), the most toxic type of DPRs in neurons, did partially develop neuropathological features of C9FTD/ALS (<xref ref-type="bibr" rid="B49">Hao et al., 2019</xref>). Two other transgenic C9FTD/ALS mouse models demonstrated that poly(GR) affects translation and stress granule dynamics (<xref ref-type="bibr" rid="B126">Zhang et al., 2018</xref>) and compromises mitochondrial function by binding Atp5a1 (<xref ref-type="bibr" rid="B26">Choi et al., 2019</xref>).</p>
</sec>
<sec id="S3">
<title>TAR DNA-Binding Protein 43 (TARDBP)</title>
<p>Mutations in the TAR DNA-binding protein 43 (the gene that encodes the TDP-43 protein) were linked to ALS in 2008 (<xref ref-type="bibr" rid="B102">Sreedharan et al., 2008</xref>). Before that, it was recognized that TDP-43 cytoplasmic and nuclear inclusions are characteristic of both ALS and FTD. In ALS, the cytoplasmic accumulation of TDP-43 is found in neurons and glia of the primary motor cortex, brainstem motor nuclei, and spinal cord (<xref ref-type="bibr" rid="B16">Bodansky et al., 2010</xref>; <xref ref-type="bibr" rid="B73">Mackenzie et al., 2010</xref>). In FTD, the inclusions are observed in the neocortex and dentate granule cells of the hippocampus (<xref ref-type="bibr" rid="B81">Neumann et al., 2006</xref>; <xref ref-type="bibr" rid="B31">Davidson et al., 2007</xref>). TDP-43 mutations are the cause of ∼ 1% of all ALS cases. In contrast, an even smaller number of FTD cases arising from mutations in this gene have been described, despite the widespread presence of TDP-43 in FTD brains (<xref ref-type="bibr" rid="B105">Tan et al., 2017</xref>).</p>
<p>TDP-43 is a DNA and RNA binding protein involved in many aspects of RNA metabolism, including splicing, microRNA biogenesis, transcription, and stabilization of messenger RNA (<xref ref-type="bibr" rid="B21">Buratti et al., 2001</xref>; <xref ref-type="bibr" rid="B103">Strong et al., 2007</xref>; <xref ref-type="bibr" rid="B19">Buratti and Baralle, 2008</xref>; <xref ref-type="bibr" rid="B40">Fiesel et al., 2010</xref>; <xref ref-type="bibr" rid="B67">Lagier-Tourenne et al., 2010</xref>). Two contrasting mechanisms have been proposed to explain TDP-43 related neurodegeneration, namely (<xref ref-type="bibr" rid="B28">Cleveland and Rothstein, 2001</xref>) loss of function arising from sequestration of critical TDP-43 protein within cytoplasmic aggregates leading to nuclear depletion of TDP-43 (<xref ref-type="bibr" rid="B25">Chio et al., 2013</xref>; <xref ref-type="bibr" rid="B76">Mitra et al., 2019</xref>; <xref ref-type="bibr" rid="B93">Roczniak-Ferguson and Ferguson, 2019</xref>) gain of function effect due to some inherent toxic property of the aggregates (<xref ref-type="bibr" rid="B20">Buratti and Baralle, 2012</xref>; <xref ref-type="bibr" rid="B51">Hergesheimer et al., 2019</xref>). However, the toxic role of aggregated TDP-43 in neurodegeneration is still under debate. Recent research has focused on the role of stress granules in the pathogenesis of TDP43-related ALS (<xref ref-type="bibr" rid="B62">Khalfallah et al., 2018</xref>). TDP-43 mutations have also been reported to alter liquid drop formation, though the pathophysiological role of this <italic>in vitro</italic> epiphenomena remains unclear (<xref ref-type="bibr" rid="B29">Conicella et al., 2016</xref>).</p>
<p>More than fifteen mouse models have been created in the last 2 years in an attempt to decipher the pathogenic roles of TDP-43 in autophagy, protein homeostasis, and clearance pathways involved in ALS and FTD. These rodent models showed that suppression of conditional TDP-43 transgene expression differentially affects early cognitive and social phenotypes in TDP-43 mice (<xref ref-type="bibr" rid="B101">Silva et al., 2019</xref>). In a TDP-43Q331K/Q331K knock-in mouse model of ALS-FTD, TDP-43 gains function due to impaired autoregulation (<xref ref-type="bibr" rid="B121">White et al., 2018b</xref>). In TDP-43M337V and TDP-43G298S knock-in mice, mutant TDP-43 causes early stage dose-dependent motor neuron degeneration (<xref ref-type="bibr" rid="B38">Ebstein et al., 2019</xref>). Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of motor neuron degeneration (<xref ref-type="bibr" rid="B42">Fratta et al., 2018</xref>). Mouse models have also provided insight into how mutations in this gene may be underlying frontotemporal dementia. A recent TDP-43Q331K mouse model manifested cognitive dysfunction in the absence of motor dysfunction. Pathological examination showed that normal localization of TDP-43 within the cell, but there was evidence of perturbed regulation of TDP-43 (<xref ref-type="bibr" rid="B120">White et al., 2018a</xref>, <xref ref-type="bibr" rid="B121">b</xref>).</p>
</sec>
<sec id="S4">
<title>Sequestosome-1 (SQSTM1)</title>
<p>Mutations in Sequestosome-1 (SQSTM1) was initially discovered in patients with Paget’s disease of bone (<xref ref-type="bibr" rid="B69">Laurin et al., 2002</xref>) and linked to ALS and behavioral FTD in 2011 (<xref ref-type="bibr" rid="B39">Fecto et al., 2011</xref>). SQSTM1 encodes p62, a multifunctional protein involved in a wide range of cellular functions, including apoptosis (<xref ref-type="bibr" rid="B60">Jung and Oh, 2019</xref>), NFKB1 signaling (<xref ref-type="bibr" rid="B41">Foster et al., 2019</xref>), ubiquitin-mediated autophagy (<xref ref-type="bibr" rid="B124">Zaffagnini et al., 2018</xref>; <xref ref-type="bibr" rid="B47">Gao et al., 2019</xref>; <xref ref-type="bibr" rid="B85">Park et al., 2019</xref>), and transcription regulation (<xref ref-type="bibr" rid="B91">Rea et al., 2013</xref>). p62 is also a standard component of ubiquitin-containing inclusions in several neurological disorders, including ALS and FTD. More than 100 variants have been identified in SQSTM1, and cumulatively they account for ∼1% of all ALS and up to 3% of all FTD cases. Defective p62 is prone to forming aggregates. Individuals with SQSTM1 variants have p62-positive inclusions in the motor neurons if presenting with ALS, and in the hippocampus and cerebral neocortex if presenting with FTD (<xref ref-type="bibr" rid="B5">Arai et al., 2003</xref>; <xref ref-type="bibr" rid="B107">Teyssou et al., 2013</xref>).</p>
<p>Accumulation of SQSTM1 comes from disturbances in the selective autophagy pathway (<xref ref-type="bibr" rid="B34">Deng et al., 2019</xref>). However, the pathogenic mechanism that contributes to SQSTM1-related impaired autophagy and degradation remains poorly understood. Similar to TDP-43 and FUS, SQSTM1 goes through liquid-liquid phase separation. Recent research shows that cytoplasmic DAXX drives SQSTM1/p62 phase condensation, an essential step in the activation of Nrf2-mediated stress response (<xref ref-type="bibr" rid="B123">Yang et al., 2019</xref>). Polyubiquitin chain-induced p62 phase separation leads to the segregation of autophagic cargo (<xref ref-type="bibr" rid="B52">Herhaus and Dikic, 2018</xref>; <xref ref-type="bibr" rid="B104">Sun et al., 2018</xref>).</p>
<p>To date, no. p62 mouse model has been created to study the direct effect of p62 mutations in ALS/FTD. However, many mouse models exist that demonstrate a relationship between p62 and other ALS genes. <xref ref-type="bibr" rid="B77">Mitsui et al. (2018)</xref> previously reported that loss of SQSTM1 exacerbates disease phenotypes in SOD1H46R ALS mice. Following the initial report, the same authors demonstrated that SQSTM1 overexpression results in a significant increase in biochemically detectable insoluble SQSTM1 and poly-ubiquitinated proteins in the spinal cord of SQSTM1; SOD1H46R mice when compared to SOD1H46R mice. This observation suggests that overexpression of p62 in SOD1H46R mice accelerates disease onset by impairing the protein degradation pathways (<xref ref-type="bibr" rid="B77">Mitsui et al., 2018</xref>).</p>
<p>From the FTD perspective, apart from developing mature-onset obesity due to impaired glucose tolerance and insulin resistance, p62 knockout mice display significantly reduced life span and accelerated aging phenotypes. These mice develop cognitive impairment and anxiety, which are symptoms characteristic of human Alzheimer’s disease (<xref ref-type="bibr" rid="B66">Kwon et al., 2012</xref>).</p>
</sec>
<sec id="S5">
<title>Fused in Sarcoma (FUS)</title>
<p>Fused in sarcoma (FUS) is an RNA-binding protein that was linked to ALS in 2009 (<xref ref-type="bibr" rid="B65">Kwiatkowski et al., 2009</xref>). Similar to TDP-43, FUS is involved in multiple aspects of RNA metabolism regulation, including alternative splicing, RNA translation, and transport (<xref ref-type="bibr" rid="B65">Kwiatkowski et al., 2009</xref>; <xref ref-type="bibr" rid="B114">Vance et al., 2009</xref>). Mutations in FUS are responsible for ∼1% of all ALS. They are also occasionally observed in behavioral FTD cases. In addition to these phenotypes, abnormal aggregates of FUS, independently of their mutations, are present in other neurodegenerative diseases such as hereditary essential tremor, the polyglutamine diseases, and Parkinson’s disease.</p>
<p>Amyotrophic lateral sclerosis and FTD related mutations are clustered in highly conserved regions of the gene and affect the protein nuclear localization signal (NLS). Similar to TDP-43, mutations in the FUS gene are predominantly found in ALS patients. A limited number of FUS mutations (p.P106L, p.Gly174-Gly175 deletion GG, p.M254V) have been described in FTD patients without concomitant ALS (<xref ref-type="bibr" rid="B111">Van Langenhove et al., 2010</xref>; <xref ref-type="bibr" rid="B55">Huey et al., 2012</xref>).</p>
<p>Two mechanisms were proposed to explain FUS-related neurodegeneration. First of all, there is the toxic gain-of-function in which nuclear FUS aggregates in cytoplasm and spreads in a prion-like manner through neuronal tissues (<xref ref-type="bibr" rid="B7">Armstrong, 2017</xref>). Second, the depletion of FUS from the nucleus may impair transcription, alternative splicing, and DNA repair (<xref ref-type="bibr" rid="B98">Shang and Huang, 2016</xref>). A reasonable amount of evidence supports both mechanisms, and different mechanisms may stand behind different FUS mutations (<xref ref-type="bibr" rid="B56">Ishigaki and Sobue, 2018</xref>; <xref ref-type="bibr" rid="B3">An et al., 2019</xref>). Liquid–liquid phase separation (LLPS) of FUS has emerged recently as an alternative mechanism for FUS-related neurodegeneration. It is now established that LLPS is modulated by universal cellular actors such as ATP and nucleic acids through enhancement and dissolution (<xref ref-type="bibr" rid="B61">Kang et al., 2019</xref>). Other recent FUS studies expanded on LLPS functions, mechanism, and transformation (<xref ref-type="bibr" rid="B14">Berry et al., 2018</xref>; <xref ref-type="bibr" rid="B61">Kang et al., 2019</xref>; <xref ref-type="bibr" rid="B79">Murthy et al., 2019</xref>; <xref ref-type="bibr" rid="B82">Niaki et al., 2019</xref>).</p>
<p>Multiple mouse models have been created in an attempt to identify the pathogenic roles of FUS in neurodegeneration. FUS knockout mice display behavioral abnormalities such as hyperactivity and reduced anxiety-related behavior. However, they do not develop motor neuron impairment, suggesting that the ablation of the FUS gene alone is insufficient to cause ALS (<xref ref-type="bibr" rid="B63">Kino et al., 2015</xref>). Transgenic mice overexpressing exogenous FUS with nuclear localization signal deletion (ΔNLS-FUS) under Thy1 neuron-specific promoter develop progressive ALS phenotypes associated with the formation of ubiquitin/p62-positive FUS aggregates, neuronal loss, and gliosis. In FusΔNLS/ΔNLS mice, truncation of the NLS region leads to mislocalization of FUS protein from the nucleus to the cytoplasm in spinal motor neurons and cortical neurons where it leads to apoptosis (<xref ref-type="bibr" rid="B97">Scekic-Zahirovic et al., 2016</xref>). Furthermore, both FusΔNLS/+mice and knock-in mice carrying another C-terminal frameshift mutation (FusΔ14/+) develop progressive motor neuron loss in heterozygosity, recapitulating the early stages of disease (<xref ref-type="bibr" rid="B97">Scekic-Zahirovic et al., 2016</xref>; <xref ref-type="bibr" rid="B36">Devoy et al., 2017</xref>). More recent FUSR514G and FUSR521C transgenic mice models show that overriding the FUS autoregulation system triggers gain-of-function toxicity via an altered autophagy-lysosome pathway and impaired RNA metabolism (<xref ref-type="bibr" rid="B53">Ho and Ling, 2019</xref>; <xref ref-type="bibr" rid="B71">Ling et al., 2019</xref>).</p>
</sec>
<sec id="S6">
<title>Valosin Containing Protein (VCP)</title>
<p>Mutations in Valosin containing protein (VCP) was initially discovered as the cause of a clinical syndrome characterized by the triad of inclusion body myopathy, Paget’s disease of bone, and frontotemporal dementia (IBMFTD) in 2004 (<xref ref-type="bibr" rid="B116">Watts et al., 2004</xref>). Mutations in this gene were subsequently identified as a cause of ALS, representing an early example of how genetic mutations in a single gene could underlie both ALS and FTD (<xref ref-type="bibr" rid="B58">Johnson et al., 2010</xref>). To date, 72 autosomal dominant mutations have been discovered in this gene, more than 30 of which are reported in ALS or FTD cases (including behavioral FTD, semantic dementia, and progressive non-fluent aphasia) (<xref ref-type="bibr" rid="B2">Al-Obeidi et al., 2018</xref>; <xref ref-type="bibr" rid="B96">Saracino et al., 2018</xref>; <xref ref-type="bibr" rid="B12">Bastola et al., 2019</xref>). Many of the reported VCP mutations are located on exon five within the N-terminal CDC48 domain, which is involved in ubiquitin-binding, meaning that mutations in this region may negatively affect the ubiquitin protein degradation pathway (<xref ref-type="bibr" rid="B46">Ganji et al., 2018</xref>; <xref ref-type="bibr" rid="B109">Twomey et al., 2019</xref>).</p>
<p>A recent study by <xref ref-type="bibr" rid="B2">Al-Obeidi et al. (2018)</xref> showed that VCP mutations are present in ∼9% of ALS, 4% of Parkinson’s disease, and 2% of Alzheimer’s disease patients. As of today, no definite correlation between the mutation type and the incidence of clinical features associated with VCP has been established (<xref ref-type="bibr" rid="B2">Al-Obeidi et al., 2018</xref>; <xref ref-type="bibr" rid="B89">Plewa et al., 2018</xref>).</p>
<p>Valosin Containing Protein encodes a member of the AAA-ATPase enzyme family with wide-ranging functions in cell division (<xref ref-type="bibr" rid="B83">Ogura and Wilkinson, 2001</xref>), DNA repair, ubiquitin-dependent protein degradation, and suppression of apoptosis (<xref ref-type="bibr" rid="B83">Ogura and Wilkinson, 2001</xref>). <xref ref-type="bibr" rid="B72">Ludtmann et al. (2017)</xref> provides evidence that mutations in VCP lead to mitochondrial uncoupling due to a reduced ADP/ATP translocation by adenine nucleotide translocase. Such deficiency in mitochondrial bioenergetics makes neurons especially vulnerable as they require more energy than other cell types (<xref ref-type="bibr" rid="B72">Ludtmann et al., 2017</xref>).</p>
<p>Recent mouse models of VCP showed that activation of the NLRP3 inflammasome is associated with VCP protein myopathy. <xref ref-type="bibr" rid="B80">Nalbandian et al. (2017)</xref> reported a significant increase in the expression of NLRP3, Caspase 1, IL-1β, and IL-18 in the quadriceps of 12 and 24 months old VCPR155H/+heterozygous mice. Furthermore, a significant increase of IL-1β(+)F4/80(+)Ly6C(+) macrophages in the quadriceps and bones of the same mice were also observed and is positively correlated with high expression levels of TDP-43 and p62/SQSTM1 markers of VCP pathology and progressive muscle wasting (<xref ref-type="bibr" rid="B80">Nalbandian et al., 2017</xref>).</p>
<p>Another recent discovery showed that VCP plays a vital role in the maintenance of lysosomal homeostasis and TFEB activity in differentiated skeletal muscle (<xref ref-type="bibr" rid="B6">Arhzaouy et al., 2019</xref>). <xref ref-type="bibr" rid="B6">Arhzaouy et al. (2019)</xref> showed that selective inactivation of VCP in skeletal muscles of Myl1p-cre-vcp-/-mice, results in a necrotic myopathy with increased macroautophagic/autophagic proteins and damaged lysosomes. It was further demonstrated that the myofiber necrosis was preceded by the upregulation of LGALS3/Galectin-3, a marker of damaged lysosomes, and TFEB activation, suggesting early defects in the lysosomal system (<xref ref-type="bibr" rid="B6">Arhzaouy et al., 2019</xref>).</p>
</sec>
<sec id="S7">
<title>Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 (CHCHD10)</title>
<p>Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) is a mitochondrial protein associated with ALS and FTD, including the behavioral and primary progressive aphasia subtypes of this form of dementia (<xref ref-type="bibr" rid="B1">Ajroud-Driss et al., 2015</xref>; <xref ref-type="bibr" rid="B30">Cozzolino et al., 2015</xref>). The protein was discovered in 2014 by exome sequencing of a large French family affected by autosomal dominant FTD with or without ALS, cerebellar ataxia, and mitochondrial myopathy (<xref ref-type="bibr" rid="B24">Chaussenot et al., 2014</xref>). At least 30 variants have since been reported, and they are concentrated on exon two of the gene encoding the non-structured N-terminal (<xref ref-type="bibr" rid="B106">Taylor et al., 2016</xref>; <xref ref-type="bibr" rid="B86">Perrone et al., 2017</xref>; <xref ref-type="bibr" rid="B127">Zhou et al., 2017</xref>).</p>
<p>Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10 is a multifunctional protein involved in the regulation of mitochondrial metabolism, synthesis of respiratory chain components, and modulation of cell apoptosis (<xref ref-type="bibr" rid="B127">Zhou et al., 2017</xref>). Perhaps not surprisingly, mutations in CHCHD10 lead to disassembly of the mitochondrial contact site complex, severe mitochondrial DNA repair deficiency after oxidative stress, disruption of oxygen consumption and ATP synthesis in cells, and disturbance of apoptotic mechanisms (<xref ref-type="bibr" rid="B127">Zhou et al., 2017</xref>).</p>
<p>Recent data shows enrichment of CHCHD10 expression at the postsynaptic membrane of neuromuscular junctions (<xref ref-type="bibr" rid="B11">Bannwarth et al., 2014</xref>; <xref ref-type="bibr" rid="B127">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="B122">Xiao et al., 2019</xref>). Deletion of CHCHD10 in skeletal muscle of HSA-CHCHD10-/- knockout mice results in motor defects and neurotransmission impairment, indicating that muscle CHCHD10 is required for normal neurotransmission between motoneurons and skeletal muscle fibers (<xref ref-type="bibr" rid="B122">Xiao et al., 2019</xref>). Furthermore, an examination of HSA-CHCHD10-/- mice mitochondria under an electron microscope revealed a large quantity of large lysosome-like vesicles, indicating active mitochondria degradation and suggesting that CHCHD10 is required for mitochondria structure and ATP production (<xref ref-type="bibr" rid="B23">Burstein et al., 2018</xref>; <xref ref-type="bibr" rid="B122">Xiao et al., 2019</xref>).</p>
<p>Two groups independently developed CHCHD10S55L knock-in mice, representative of human CHCHD10 S59L mutation, and found that these mice developed progressive motor deficits, myopathy, cardiomyopathy, and died prematurely (<xref ref-type="bibr" rid="B4">Anderson et al., 2019</xref>; <xref ref-type="bibr" rid="B48">Genin et al., 2019</xref>). Histological examination revealed that CHCHD10, together with its twin CHCHD2 forms aggregates resulting in abnormal organelle morphology and function. In contrast, knock out CHCHD10 mice containing a single adenine nucleotide insertion in exon two that results in a prematurely terminated protein, did not develop similar pathology, suggesting that tissue-specific toxic gain-of-function is the likely mechanism behind CHCHD10 S59L related neurodegeneration (<xref ref-type="bibr" rid="B4">Anderson et al., 2019</xref>).</p>
</sec>
<sec id="S8">
<title>TANK-Binding Kinase 1 (TBK1)</title>
<p>TANK-binding kinase 1 (TBK1) gene was discovered in 2015 through the whole-exome sequencing analysis of a large case-control cohort (<xref ref-type="bibr" rid="B27">Cirulli et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Freischmidt et al., 2015</xref>). In 2016, a large genome-wide association study (GWAS) also identified the TBK1 gene on chromosome 12q14.2 as a risk locus for ALS, thus confirming the gene’s association with motor neuron degeneration (<xref ref-type="bibr" rid="B113">van Rheenen et al., 2016</xref>). TBK1 is a member of the IkB kinase family involved in autophagy, mitophagy, and innate immune signaling (<xref ref-type="bibr" rid="B117">Weidberg and Elazar, 2011</xref>). The protein is highly expressed in neuronal cells of the cerebral cortex, hippocampus, and lateral ventricle (<xref ref-type="bibr" rid="B110">Uhlen et al., 2015</xref>). It also interacts with other genes implicated in ALS, such as OPTN and SQSTM1, to form TBK1 autophagic adaptor complex (<xref ref-type="bibr" rid="B95">Ryzhakov and Randow, 2007</xref>; <xref ref-type="bibr" rid="B78">Morton et al., 2008</xref>; <xref ref-type="bibr" rid="B70">Li et al., 2016</xref>).</p>
<p>To date, more than 90 mutations have been discovered on TBK1. According to a recent meta-analysis study, TBK1 loss of function and missense mutations account for 1.0 and 1.8% in ALS/FTD patients, respectively (<xref ref-type="bibr" rid="B68">Lamb et al., 2019</xref>). The majority of TBK1 mutations are loss of function that result in the deletion of the C-terminal domain responsible for interaction with adaptor proteins that regulate the cellular distribution of TBK1 and activation of downstream signaling pathways (<xref ref-type="bibr" rid="B95">Ryzhakov and Randow, 2007</xref>). Indeed, mutations appear to lead to a significant decrease in TBK1 expression at the mRNA and protein levels (<xref ref-type="bibr" rid="B45">Freischmidt et al., 2015</xref>).</p>
<p>TANK-binding kinase 1 mutations are associated with bulbar onset ALS and fast progressing behavioral FTD (<xref ref-type="bibr" rid="B45">Freischmidt et al., 2015</xref>). In ALS patients, TBK1 mutations are pathologically characterized by TDP-43 positive and p62 positive inclusions in motor neurons, as well as TDP-43 inclusions in the cortex. Similar to that observed in ALS, FTD patients, harboring TBK1 mutations is also characterized by TDP-43 inclusions in numerous brain regions and cytoplasmic p62 and ubiquitin-positive inclusions in glial cells (<xref ref-type="bibr" rid="B112">Van Mossevelde et al., 2016</xref>).</p>
<p>Compelling evidence exists that loss-of-function is the pathological mechanism behind TBK1-related ALS and FTD (<xref ref-type="bibr" rid="B32">de Majo et al., 2018</xref>; <xref ref-type="bibr" rid="B68">Lamb et al., 2019</xref>; <xref ref-type="bibr" rid="B118">Weinreich et al., 2019</xref>). Germline deletion of TBK1 is lethal in embryonic mice suggesting that the protein plays a critical role in developmental homeostasis (<xref ref-type="bibr" rid="B17">Bonnard et al., 2000</xref>). More recent rodent models demonstrated that conditional neuron-specific knockout of Tbk1 in Tbk1fl/fl Nestin-Cre mice leads to the development of cognitive and motor dysfunction similar to ALS/FTD. Neuron-specific Tbk1 deletion induces morphological and biochemical alterations in neurons and glia such as abnormal dendrites, neurofibrillary tangles, reduced dendritic spine density, as well as cortical synapse loss. Furthermore, Tbk1 knockout impairs autophagy in motor neuron-like cells, while Tbk1 over-expression extends survival of ALS transgenic mice (<xref ref-type="bibr" rid="B37">Duan et al., 2019</xref>).</p>
<p>TANK-Binding Kinase 1 is a central regulator of selective autophagy and inflammatory responses via IFN type I signaling (<xref ref-type="bibr" rid="B87">Perry et al., 2004</xref>; <xref ref-type="bibr" rid="B54">Hu et al., 2018</xref>). Heterozygous deletion of the α-IFN receptor Ifnar1 significantly prolongs the life span of SOD1G93A ALS mice (<xref ref-type="bibr" rid="B115">Wang et al., 2011</xref>). In a 2019 study, <xref ref-type="bibr" rid="B18">Brenner et al. (2019)</xref> further elucidated on the connection between TBK1 and SOD1 in the mouse models. The group showed that at the early stage, heterozygous Tbk1 deletion impairs autophagy in motoneurons and prepones the clinical onset and muscular denervation in SOD1G93A/Tbk1 ± mice, while at the late disease stage, it significantly alleviates microglial neuroinflammation, decelerates disease progression, and extends mouse survival (<xref ref-type="bibr" rid="B18">Brenner et al., 2019</xref>).</p>
<sec id="S8.SS1">
<title>Summary</title>
<p>After several decades of research, it is now clear that the same genes can cause ALS and FTD. Mutations in C9orf72, TARDBP, FUS, TBK1, VCP, CHCHD10, and SQSTM1 are the most closely associated with both diseases. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.</p>
<p>Nevertheless, this overlap is not complete: SOD1, FUS, and TDP-43 variants are most commonly associated with ALS and are only rarely found in FTD patients. Similarly, GRN is linked to FTD, but not to ALS. Clinically, the ALS phenotype is most commonly associated with the behavioral variant of FTD, with other subtypes of FTD involving language occurring less commonly. The pathophysiology underlying this observation is poorly understood.</p>
<p>It is striking how the same pathways are implicated repeatedly in ALS and FTD. Both disorders characterized by defects in RNA processing, protein clearance by autophagy, vesicle trafficking, mitochondrial dysfunction, and impaired protein homeostasis. The genes described in this review are the key players in these pathways. TDP-43 and FUS are responsible for RNA regulation; SQSTM1, C9orf72, VCP, and TBK1 are involved in autophagy and vesicle dynamics; TDP-43, FUS, and SQSTM1 are common components of nuclear and cytoplasmic inclusions (<xref ref-type="bibr" rid="B119">Weishaupt et al., 2016</xref>). Due to such significant genetic overlap between ALS and FTD, it is reasonable to look in FTD cases for mutations in ALS genes, and vice-versa.</p>
<p>The C9orf72 repeat expansion gives rise to a diverse range of inter-familial and intra-familial phenotypes, including age at disease onset, site of symptom onset, rate and pattern of progression, levels of cognitive impairment and motor neuron degeneration, as well as disease duration. This clinical heterogeneity likely indicates that both genetic and environmental factors play a significant role in the development and course of the disease. Environmental factors such as occupational exposure to heavy metals, toxic compounds, and extremely low-frequency electromagnetic frequencies have been previously reported to increase the risk of developing neurological disorders. Studies on personal habits revealed an increased risk of ALS among smokers, as well as an overall worse prognosis after disease onset. In contrast, alcohol consumption was associated with a reduced risk of ALS. Literature analysis of head trauma and the development of neurological disorders were inconclusive. More recently, advanced genetic analysis of a large genetic dataset implicated high cholesterol as driving the risk of ALS, as well as confirming an association with smoking and physical exercise (<xref ref-type="bibr" rid="B10">Bandres-Ciga et al., 2019</xref>).</p>
<p>Research shows that environmental factors can influence people’s chances of developing ALS or FTD. Nevertheless, the studies were performed on case cohorts that were not genetically selected. Different sets of environmental factors may interact with different genes. Consequently, future genetic epidemiology efforts should focus on cohorts selected based on their underlying genetic risk. Studying such population-based cohorts that have been assiduously collected and phenotyped for clinical features, genetics, epigenetics, and environmental and lifestyle exposures will be essential to these efforts.</p>
</sec>
</sec>
<sec id="S9">
<title>Author Contributions</title>
<p>YA drafted the manuscript. PF, RC, and BT participated in critically revising the manuscript for important intellectual content. All authors read and approved the final manuscript.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>BT has a European patent granted and US patent pending on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a past co-authorship with one of the authors BT. The reviewer PM declared a past co-authorship with one of the authors BT to the handling Editor.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported in part by the Intramural Research Programs of the U.S. National Institutes of Health, National Institute on Aging (Z01-AG000949-02) and the National Institute of Neurological Disorders and Stroke. This work was also supported by University College London.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajroud-Driss</surname><given-names>S.</given-names></name><name><surname>Fecto</surname><given-names>F.</given-names></name><name><surname>Ajroud</surname><given-names>K.</given-names></name><name><surname>Lalani</surname><given-names>I.</given-names></name><name><surname>Calvo</surname><given-names>S. E.</given-names></name><name><surname>Mootha</surname><given-names>V. K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy.</article-title>
<source/><italic>Neurogenetics</italic>
<volume>16</volume>
<fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10048-014-0421-1</pub-id>
<pub-id pub-id-type="pmid">25193783</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Obeidi</surname><given-names>E.</given-names></name><name><surname>Al-Tahan</surname><given-names>S.</given-names></name><name><surname>Surampalli</surname><given-names>A.</given-names></name><name><surname>Goyal</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>A. K.</given-names></name><name><surname>Hermann</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy.</article-title>
<source/><italic>Clin. Genet.</italic>
<volume>93</volume>
<fpage>119</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/cge.13095</pub-id>
<pub-id pub-id-type="pmid">28692196</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>H.</given-names></name><name><surname>Skelt</surname><given-names>L.</given-names></name><name><surname>Notaro</surname><given-names>A.</given-names></name><name><surname>Highley</surname><given-names>J. R.</given-names></name><name><surname>Fox</surname><given-names>A. H.</given-names></name><name><surname>La Bella</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles.</article-title>
<source/><italic>Acta Neuropathol. Commun.</italic>
<volume>7</volume>:<issue>7</issue>. <pub-id pub-id-type="doi">10.1186/s40478-019-0658-x</pub-id>
<pub-id pub-id-type="pmid">30642400</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C. J.</given-names></name><name><surname>Bredvik</surname><given-names>K.</given-names></name><name><surname>Burstein</surname><given-names>S. R.</given-names></name><name><surname>Davis</surname><given-names>C.</given-names></name><name><surname>Meadows</surname><given-names>S. M.</given-names></name><name><surname>Dash</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>138</volume>
<fpage>103</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-019-01989-y</pub-id>
<pub-id pub-id-type="pmid">30877432</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>T.</given-names></name><name><surname>Nonaka</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>M.</given-names></name><name><surname>Akiyama</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Hashizume</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>342</volume>
<fpage>41</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="pmid">12727313</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arhzaouy</surname><given-names>K.</given-names></name><name><surname>Papadopoulos</surname><given-names>C.</given-names></name><name><surname>Schulze</surname><given-names>N.</given-names></name><name><surname>Pittman</surname><given-names>S. K.</given-names></name><name><surname>Meyer</surname><given-names>H.</given-names></name><name><surname>Weihl</surname><given-names>C. C.</given-names></name></person-group> (<year>2019</year>). <article-title>VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle.</article-title>
<source/><italic>Autophagy</italic>
<volume>15</volume>
<fpage>1082</fpage>–<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1569933</pub-id>
<pub-id pub-id-type="pmid">30654731</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>R. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.</article-title>
<source/><italic>Folia Neuropathol.</italic>
<volume>55</volume>
<fpage>185</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.5114/fn.2017.70482</pub-id>
<pub-id pub-id-type="pmid">28984110</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>K. C.</given-names></name><name><surname>Calvo</surname><given-names>A.</given-names></name><name><surname>Price</surname><given-names>T. R.</given-names></name><name><surname>Geiger</surname><given-names>J. T.</given-names></name><name><surname>Chio</surname><given-names>A.</given-names></name><name><surname>Traynor</surname><given-names>B. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>7</volume>:<issue>12408</issue>. <pub-id pub-id-type="doi">10.1038/ncomms12408</pub-id>
<pub-id pub-id-type="pmid">27510634</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arzberger</surname><given-names>T.</given-names></name><name><surname>Schludi</surname><given-names>M. H.</given-names></name><name><surname>Lehmer</surname><given-names>C.</given-names></name><name><surname>Schmid</surname><given-names>B.</given-names></name><name><surname>Edbauer</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>RNA versus protein toxicity in C9orf72 ALS/FTLD.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>135</volume>
<fpage>475</fpage>–<lpage>479</lpage>.<pub-id pub-id-type="pmid">29450647</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandres-Ciga</surname><given-names>S.</given-names></name><name><surname>Noyce</surname><given-names>A. J.</given-names></name><name><surname>Hemani</surname><given-names>G.</given-names></name><name><surname>Nicolas</surname><given-names>A.</given-names></name><name><surname>Calvo</surname><given-names>A.</given-names></name><name><surname>Mora</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>85</volume>
<fpage>470</fpage>–<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1002/ana.25431</pub-id>
<pub-id pub-id-type="pmid">30723964</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannwarth</surname><given-names>S.</given-names></name><name><surname>Ait-El-Mkadem</surname><given-names>S.</given-names></name><name><surname>Chaussenot</surname><given-names>A.</given-names></name><name><surname>Genin</surname><given-names>E. C.</given-names></name><name><surname>Lacas-Gervais</surname><given-names>S.</given-names></name><name><surname>Fragaki</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.</article-title>
<source/><italic>Brain</italic>
<volume>137(Pt 8)</volume>, <fpage>2329</fpage>–<lpage>2345</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awu138</pub-id>
<pub-id pub-id-type="pmid">24934289</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastola</surname><given-names>P.</given-names></name><name><surname>Bilkis</surname><given-names>R.</given-names></name><name><surname>De Souza</surname><given-names>C.</given-names></name><name><surname>Minn</surname><given-names>K.</given-names></name><name><surname>Chien</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>9</volume>:<issue>11002</issue>. <pub-id pub-id-type="doi">10.1038/s41598-019-47085-9</pub-id>
<pub-id pub-id-type="pmid">31358864</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>J.</given-names></name><name><surname>Poulter</surname><given-names>M.</given-names></name><name><surname>Hensman</surname><given-names>D.</given-names></name><name><surname>Rohrer</surname><given-names>J. D.</given-names></name><name><surname>Mahoney</surname><given-names>C. J.</given-names></name><name><surname>Adamson</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.</article-title>
<source/><italic>Am. J. Hum. Genet.</italic>
<volume>92</volume>
<fpage>345</fpage>–<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2013.01.011</pub-id>
<pub-id pub-id-type="pmid">23434116</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>J.</given-names></name><name><surname>Brangwynne</surname><given-names>C. P.</given-names></name><name><surname>Haataja</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Physical principles of intracellular organization via active and passive phase transitions.</article-title>
<source/><italic>Rep. Prog. Phys.</italic>
<volume>81</volume>:<issue>046601</issue>. <pub-id pub-id-type="doi">10.1088/1361-6633/aaa61e</pub-id>
<pub-id pub-id-type="pmid">29313527</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>T. D.</given-names></name><name><surname>Nochlin</surname><given-names>D.</given-names></name><name><surname>Poorkaj</surname><given-names>P.</given-names></name><name><surname>Cherrier</surname><given-names>M.</given-names></name><name><surname>Kaye</surname><given-names>J.</given-names></name><name><surname>Payami</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>1999</year>). <article-title>A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L).</article-title>
<source/><italic>Brain</italic>
<volume>122(Pt 4)</volume>, <fpage>741</fpage>–<lpage>756</lpage>. <pub-id pub-id-type="pmid">10219785</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodansky</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>J. M.</given-names></name><name><surname>Tempest</surname><given-names>L.</given-names></name><name><surname>Velagapudi</surname><given-names>A.</given-names></name><name><surname>Libby</surname><given-names>R.</given-names></name><name><surname>Ravits</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread.</article-title>
<source/><italic>Amyotroph. Lateral. Scler.</italic>
<volume>11</volume>
<fpage>321</fpage>–<lpage>327</lpage>. <pub-id pub-id-type="doi">10.3109/17482961003602363</pub-id>
<pub-id pub-id-type="pmid">20225928</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnard</surname><given-names>M.</given-names></name><name><surname>Mirtsos</surname><given-names>C.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Graham</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Ng</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription.</article-title>
<source/><italic>EMBO J.</italic>
<volume>19</volume>
<fpage>4976</fpage>–<lpage>4985</lpage>. <pub-id pub-id-type="pmid">10990461</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>D.</given-names></name><name><surname>Sieverding</surname><given-names>K.</given-names></name><name><surname>Bruno</surname><given-names>C.</given-names></name><name><surname>Luningschror</surname><given-names>P.</given-names></name><name><surname>Buck</surname><given-names>E.</given-names></name><name><surname>Mungwa</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice.</article-title>
<source/><italic>J. Exp. Med.</italic>
<volume>216</volume>
<fpage>267</fpage>–<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20180729</pub-id>
<pub-id pub-id-type="pmid">30635357</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E.</given-names></name><name><surname>Baralle</surname><given-names>F. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease.</article-title>
<source/><italic>Front Biosci.</italic>
<volume>13</volume>:<fpage>867</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">17981595</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E.</given-names></name><name><surname>Baralle</surname><given-names>F. E.</given-names></name></person-group> (<year>2012</year>). <article-title>TDP-43: gumming up neurons through protein-protein and protein-RNA interactions.</article-title>
<source/><italic>Trends Biochem. Sci.</italic>
<volume>37</volume>
<fpage>237</fpage>–<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2012.03.003</pub-id>
<pub-id pub-id-type="pmid">22534659</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buratti</surname><given-names>E.</given-names></name><name><surname>Dork</surname><given-names>T.</given-names></name><name><surname>Zuccato</surname><given-names>E.</given-names></name><name><surname>Pagani</surname><given-names>F.</given-names></name><name><surname>Romano</surname><given-names>M.</given-names></name><name><surname>Baralle</surname><given-names>F. E.</given-names></name></person-group> (<year>2001</year>). <article-title>Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.</article-title>
<source/><italic>EMBO J.</italic>
<volume>20</volume>
<fpage>1774</fpage>–<lpage>1784</lpage>. <pub-id pub-id-type="pmid">11285240</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrell</surname><given-names>J. R.</given-names></name><name><surname>Kiernan</surname><given-names>M. C.</given-names></name><name><surname>Vucic</surname><given-names>S.</given-names></name><name><surname>Hodges</surname><given-names>J. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Motor neuron dysfunction in frontotemporal dementia.</article-title>
<source/><italic>Brain</italic>
<volume>134(Pt 9)</volume>, <fpage>2582</fpage>–<lpage>2594</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awr195</pub-id>
<pub-id pub-id-type="pmid">21840887</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>S. R.</given-names></name><name><surname>Valsecchi</surname><given-names>F.</given-names></name><name><surname>Kawamata</surname><given-names>H.</given-names></name><name><surname>Bourens</surname><given-names>M.</given-names></name><name><surname>Zeng</surname><given-names>R.</given-names></name><name><surname>Zuberi</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>27</volume>
<fpage>160</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddx397</pub-id>
<pub-id pub-id-type="pmid">29112723</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaussenot</surname><given-names>A.</given-names></name><name><surname>Le Ber</surname><given-names>I.</given-names></name><name><surname>Ait-El-Mkadem</surname><given-names>S.</given-names></name><name><surname>Camuzat</surname><given-names>A.</given-names></name><name><surname>de Septenville</surname><given-names>A.</given-names></name><name><surname>Bannwarth</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>35</volume>
<fpage>e1</fpage>–<lpage>e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.07.022</pub-id>
<pub-id pub-id-type="pmid">24099785</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chio</surname><given-names>A.</given-names></name><name><surname>Logroscino</surname><given-names>G.</given-names></name><name><surname>Traynor</surname><given-names>B. J.</given-names></name><name><surname>Collins</surname><given-names>J.</given-names></name><name><surname>Simeone</surname><given-names>J. C.</given-names></name><name><surname>Goldstein</surname><given-names>L. A.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature.</article-title>
<source/><italic>Neuroepidemiology</italic>
<volume>41</volume>
<fpage>118</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1159/000351153</pub-id>
<pub-id pub-id-type="pmid">23860588</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S. Y.</given-names></name><name><surname>Lopez-Gonzalez</surname><given-names>R.</given-names></name><name><surname>Krishnan</surname><given-names>G.</given-names></name><name><surname>Phillips</surname><given-names>H. L.</given-names></name><name><surname>Li</surname><given-names>A. N.</given-names></name><name><surname>Seeley</surname><given-names>W. W.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>22</volume>
<fpage>851</fpage>–<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-019-0397-0</pub-id>
<pub-id pub-id-type="pmid">31086314</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirulli</surname><given-names>E. T.</given-names></name><name><surname>Lasseigne</surname><given-names>B. N.</given-names></name><name><surname>Petrovski</surname><given-names>S.</given-names></name><name><surname>Sapp</surname><given-names>P. C.</given-names></name><name><surname>Dion</surname><given-names>P. A.</given-names></name><name><surname>Leblond</surname><given-names>C. S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.</article-title>
<source/><italic>Science</italic>
<volume>347</volume>
<fpage>1436</fpage>–<lpage>1441</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa3650</pub-id>
<pub-id pub-id-type="pmid">25700176</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleveland</surname><given-names>D. W.</given-names></name><name><surname>Rothstein</surname><given-names>J. D.</given-names></name></person-group> (<year>2001</year>). <article-title>From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>2</volume>
<fpage>806</fpage>–<lpage>819</lpage>.<pub-id pub-id-type="pmid">11715057</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conicella</surname><given-names>A. E.</given-names></name><name><surname>Zerze</surname><given-names>G. H.</given-names></name><name><surname>Mittal</surname><given-names>J.</given-names></name><name><surname>Fawzi</surname><given-names>N. L.</given-names></name></person-group> (<year>2016</year>). <article-title>ALS mutations disrupt phase separation mediated by alpha-helical structure in the TDP-43 low-complexity C-terminal domain.</article-title>
<source/><italic>Structure</italic>
<volume>24</volume>
<fpage>1537</fpage>–<lpage>1549</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2016.07.007</pub-id>
<pub-id pub-id-type="pmid">27545621</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cozzolino</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>S.</given-names></name><name><surname>Mirra</surname><given-names>A.</given-names></name><name><surname>Carri</surname><given-names>M. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Mitochondrial dynamism and the pathogenesis of Amyotrophic Lateral Sclerosis.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>9</volume>:<issue>31</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00031</pub-id>
<pub-id pub-id-type="pmid">25713513</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>Y.</given-names></name><name><surname>Kelley</surname><given-names>T.</given-names></name><name><surname>Mackenzie</surname><given-names>I. R.</given-names></name><name><surname>Pickering-Brown</surname><given-names>S.</given-names></name><name><surname>Du Plessis</surname><given-names>D.</given-names></name><name><surname>Neary</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein. TDP-43.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>113</volume>
<fpage>521</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="pmid">17219193</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Majo</surname><given-names>M.</given-names></name><name><surname>Topp</surname><given-names>S. D.</given-names></name><name><surname>Smith</surname><given-names>B. N.</given-names></name><name><surname>Nishimura</surname><given-names>A. L.</given-names></name><name><surname>Chen</surname><given-names>H. J.</given-names></name><name><surname>Gkazi</surname><given-names>A. S.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>71</volume>
<fpage>e1</fpage>–<lpage>e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.06.015</pub-id>
<pub-id pub-id-type="pmid">30033073</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeJesus-Hernandez</surname><given-names>M.</given-names></name><name><surname>Mackenzie</surname><given-names>I. R.</given-names></name><name><surname>Boeve</surname><given-names>B. F.</given-names></name><name><surname>Boxer</surname><given-names>A. L.</given-names></name><name><surname>Baker</surname><given-names>M.</given-names></name><name><surname>Rutherford</surname><given-names>N. J.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.</article-title>
<source/><italic>Neuron</italic>
<volume>2011</volume>
<fpage>245</fpage>–<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.09.011</pub-id>
<pub-id pub-id-type="pmid">21944778</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Lim</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Purtell</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Palomo</surname><given-names>G. M.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway.</article-title>
<source/><italic>Autophagy</italic>
<pub-id pub-id-type="doi">10.1080/15548627.2019.1644076</pub-id>
<comment>[Epub ahead of print]</comment>, <pub-id pub-id-type="pmid">31362587</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devenney</surname><given-names>E. M.</given-names></name><name><surname>Ahmed</surname><given-names>R. M.</given-names></name><name><surname>Halliday</surname><given-names>G.</given-names></name><name><surname>Piguet</surname><given-names>O.</given-names></name><name><surname>Kiernan</surname><given-names>M. C.</given-names></name><name><surname>Hodges</surname><given-names>J. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members.</article-title>
<source/><italic>Neurology</italic>
<volume>91</volume>
<fpage>e1498</fpage>–<lpage>e1507</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000006344</pub-id>
<pub-id pub-id-type="pmid">30258023</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devoy</surname><given-names>A.</given-names></name><name><surname>Kalmar</surname><given-names>B.</given-names></name><name><surname>Stewart</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Burke</surname><given-names>B.</given-names></name><name><surname>Noy</surname><given-names>S. J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in ‘FUSDelta14’ knockin mice.</article-title>
<source/><italic>Brain</italic>
<volume>140</volume>
<fpage>2797</fpage>–<lpage>2805</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx248</pub-id>
<pub-id pub-id-type="pmid">29053787</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>M.</given-names></name><name><surname>Yi</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice.</article-title>
<source/><italic>Aging</italic>
<volume>11</volume>
<fpage>2457</fpage>–<lpage>2476</lpage>. <pub-id pub-id-type="doi">10.18632/aging.101936</pub-id>
<pub-id pub-id-type="pmid">31039129</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebstein</surname><given-names>S. Y.</given-names></name><name><surname>Yagudayeva</surname><given-names>I.</given-names></name><name><surname>Shneider</surname><given-names>N. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a tardbp knockin mouse model of ALS.</article-title>
<source/><italic>Cell Rep</italic>
<volume>26</volume>:<issue>364-373e4</issue>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.12.045</pub-id>
<pub-id pub-id-type="pmid">30625319</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecto</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Vemula</surname><given-names>S. P.</given-names></name><name><surname>Liu</surname><given-names>E.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis.</article-title>
<source/><italic>Arch Neurol.</italic>
<volume>68</volume>
<fpage>1440</fpage>–<lpage>1446</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2011.250</pub-id>
<pub-id pub-id-type="pmid">22084127</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiesel</surname><given-names>F. C.</given-names></name><name><surname>Voigt</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>S. S.</given-names></name><name><surname>Van den Haute</surname><given-names>C.</given-names></name><name><surname>Waldenmaier</surname><given-names>A.</given-names></name><name><surname>Gorner</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6.</article-title>
<source/><italic>EMBO J.</italic>
<volume>29</volume>
<fpage>209</fpage>–<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2009.324</pub-id>
<pub-id pub-id-type="pmid">19910924</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>D.</given-names></name><name><surname>Layfield</surname><given-names>R.</given-names></name><name><surname>Rea</surname><given-names>S. L.</given-names></name></person-group> (<year>2019</year>). <article-title>An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-kappaB signalling and is associated with reduced phosphorylation of p62.</article-title>
<source/><italic>Mol. Cell Neurosci.</italic>
<volume>98</volume>
<fpage>32</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2019.04.001</pub-id>
<pub-id pub-id-type="pmid">30954537</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fratta</surname><given-names>P.</given-names></name><name><surname>Sivakumar</surname><given-names>P.</given-names></name><name><surname>Humphrey</surname><given-names>J.</given-names></name><name><surname>Lo</surname><given-names>K.</given-names></name><name><surname>Ricketts</surname><given-names>T.</given-names></name><name><surname>Oliveira</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis.</article-title>
<source/><italic>EMBO J.</italic>
<volume>37</volume>:<issue>e98684</issue>. <pub-id pub-id-type="doi">10.15252/embj.201798684</pub-id>
<pub-id pub-id-type="pmid">29764981</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freibaum</surname><given-names>B. D.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Lopez-Gonzalez</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>N. C.</given-names></name><name><surname>Almeida</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport.</article-title>
<source/><italic>Nature</italic>
<volume>525</volume>
<fpage>129</fpage>–<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1038/nature14974</pub-id>
<pub-id pub-id-type="pmid">26308899</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freibaum</surname><given-names>B. D.</given-names></name><name><surname>Taylor</surname><given-names>J. P.</given-names></name></person-group> (<year>2017</year>). <article-title>The role of dipeptide repeats in C9ORF72-related ALS-FTD.</article-title>
<source/><italic>Front. Mol. Neurosci.</italic>
<volume>10</volume>:<issue>35</issue>. <pub-id pub-id-type="doi">10.3389/fnmol.2017.00035</pub-id>
<pub-id pub-id-type="pmid">28243191</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freischmidt</surname><given-names>A.</given-names></name><name><surname>Wieland</surname><given-names>T.</given-names></name><name><surname>Richter</surname><given-names>B.</given-names></name><name><surname>Ruf</surname><given-names>W.</given-names></name><name><surname>Schaeffer</surname><given-names>V.</given-names></name><name><surname>Muller</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>18</volume>
<fpage>631</fpage>–<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4000</pub-id>
<pub-id pub-id-type="pmid">25803835</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganji</surname><given-names>R.</given-names></name><name><surname>Mukkavalli</surname><given-names>S.</given-names></name><name><surname>Somanji</surname><given-names>F.</given-names></name><name><surname>Raman</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>The VCP-UBXN1 complex mediates triage of ubiquitylated cytosolic proteins bound to the BAG6 complex.</article-title>
<source/><italic>Mol. Cell Biol.</italic>
<volume>38</volume>:<issue>MCB.00154-118</issue>. <pub-id pub-id-type="doi">10.1128/MCB.00154-18</pub-id>
<pub-id pub-id-type="pmid">29685906</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Perera</surname><given-names>G.</given-names></name><name><surname>Bhadbhade</surname><given-names>M.</given-names></name><name><surname>Halliday</surname><given-names>G. M.</given-names></name><name><surname>Dzamko</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>). <article-title>Autophagy activation promotes clearance of alpha-synuclein inclusions in fibril-seeded human neural cells.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>294</volume>
<fpage>14241</fpage>–<lpage>14256</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.RA119.008733</pub-id>
<pub-id pub-id-type="pmid">31375560</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genin</surname><given-names>E. C.</given-names></name><name><surname>Madji Hounoum</surname><given-names>B.</given-names></name><name><surname>Bannwarth</surname><given-names>S.</given-names></name><name><surname>Fragaki</surname><given-names>K.</given-names></name><name><surname>Lacas-Gervais</surname><given-names>S.</given-names></name><name><surname>Mauri-Crouzet</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10(S59L/+) mouse.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>138</volume>
<fpage>123</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-019-01988-z</pub-id>
<pub-id pub-id-type="pmid">30874923</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>10</volume>:<issue>2906</issue>. <pub-id pub-id-type="doi">10.1038/s41467-019-10956-w</pub-id>
<pub-id pub-id-type="pmid">31266945</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensman Moss</surname><given-names>D. J.</given-names></name><name><surname>Poulter</surname><given-names>M.</given-names></name><name><surname>Beck</surname><given-names>J.</given-names></name><name><surname>Hehir</surname><given-names>J.</given-names></name><name><surname>Polke</surname><given-names>J. M.</given-names></name><name><surname>Campbell</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.</article-title>
<source/><italic>Neurology</italic>
<volume>82</volume>
<fpage>292</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000000061</pub-id>
<pub-id pub-id-type="pmid">24363131</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hergesheimer</surname><given-names>R. C.</given-names></name><name><surname>Chami</surname><given-names>A. A.</given-names></name><name><surname>de Assis</surname><given-names>D. R.</given-names></name><name><surname>Vourc’h</surname><given-names>P.</given-names></name><name><surname>Andres</surname><given-names>C. R.</given-names></name><name><surname>Corcia</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?</article-title>
<source/><italic>Brain</italic>
<volume>142</volume>
<fpage>1176</fpage>–<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awz078</pub-id>
<pub-id pub-id-type="pmid">30938443</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herhaus</surname><given-names>L.</given-names></name><name><surname>Dikic</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Ubiquitin-induced phase separation of p62/SQSTM1.</article-title>
<source/><italic>Cell Res.</italic>
<volume>28</volume>
<fpage>389</fpage>–<lpage>390</lpage>.<pub-id pub-id-type="pmid">29572488</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>W. Y.</given-names></name><name><surname>Ling</surname><given-names>S. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Elevated FUS levels by overriding its autoregulation produce gain-of-toxicity properties that disrupt protein and RNA homeostasis.</article-title>
<source/><italic>Autophagy</italic>
<volume>15</volume>
<fpage>1665</fpage>–<lpage>1667</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1633162</pub-id>
<pub-id pub-id-type="pmid">31230528</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y. W.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X. M.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Nie</surname><given-names>P.</given-names></name><name><surname>Chang</surname><given-names>M. X.</given-names></name></person-group> (<year>2018</year>). <article-title>TANK-binding kinase 1 (TBK1) isoforms negatively regulate type I Interferon Induction by inhibiting TBK1-IRF3 interaction and IRF3 phosphorylation.</article-title>
<source/><italic>Front. Immunol.</italic>
<volume>9</volume>:<issue>84</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00084</pub-id>
<pub-id pub-id-type="pmid">29441066</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huey</surname><given-names>E. D.</given-names></name><name><surname>Ferrari</surname><given-names>R.</given-names></name><name><surname>Moreno</surname><given-names>J. H.</given-names></name><name><surname>Jensen</surname><given-names>C.</given-names></name><name><surname>Morris</surname><given-names>C. M.</given-names></name><name><surname>Potocnik</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>FUS and TDP43 genetic variability in FTD and CBS.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>33</volume>
<fpage>e9</fpage>–<lpage>e17</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.08.004</pub-id>
<pub-id pub-id-type="pmid">21943958</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishigaki</surname><given-names>S.</given-names></name><name><surname>Sobue</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>Importance of functional loss of FUS in FTLD/ALS.</article-title>
<source/><italic>Front. Mol. Biosci.</italic>
<volume>5</volume>:<issue>44</issue>. <pub-id pub-id-type="doi">10.3389/fmolb.2018.00044</pub-id>
<pub-id pub-id-type="pmid">29774215</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Gendron</surname><given-names>T. F.</given-names></name><name><surname>Saberi</surname><given-names>S.</given-names></name><name><surname>McAlonis-Downes</surname><given-names>M.</given-names></name><name><surname>Seelman</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs.</article-title>
<source/><italic>Neuron</italic>
<volume>90</volume>
<fpage>535</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27112497</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J. O.</given-names></name><name><surname>Mandrioli</surname><given-names>J.</given-names></name><name><surname>Benatar</surname><given-names>M.</given-names></name><name><surname>Abramzon</surname><given-names>Y.</given-names></name><name><surname>Van Deerlin</surname><given-names>V. M.</given-names></name><name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Exome sequencing reveals VCP mutations as a cause of familial ALS.</article-title>
<source/><italic>Neuron</italic>
<volume>68</volume>
<fpage>857</fpage>–<lpage>864</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.11.036</pub-id>
<pub-id pub-id-type="pmid">21145000</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jovicic</surname><given-names>A.</given-names></name><name><surname>Mertens</surname><given-names>J.</given-names></name><name><surname>Boeynaems</surname><given-names>S.</given-names></name><name><surname>Bogaert</surname><given-names>E.</given-names></name><name><surname>Chai</surname><given-names>N.</given-names></name><name><surname>Yamada</surname><given-names>S. B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>18</volume>
<fpage>1226</fpage>–<lpage>1229</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4085</pub-id>
<pub-id pub-id-type="pmid">26308983</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>K. T.</given-names></name><name><surname>Oh</surname><given-names>S. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Polyubiquitination of p62/SQSTM1 is a prerequisite for Fas/CD95 aggregation to promote caspase-dependent apoptosis in cadmium-exposed mouse monocyte RAW264.7 cells.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>9</volume>:<issue>12240</issue>. <pub-id pub-id-type="doi">10.1038/s41598-019-48684-2</pub-id>
<pub-id pub-id-type="pmid">31439879</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Lim</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>A unified mechanism for LLPS of ALS/FTLD-causing FUS as well as its modulation by ATP and oligonucleic acids.</article-title>
<source/><italic>PLoS Biol.</italic>
<volume>17</volume>:<issue>e3000327</issue>. <pub-id pub-id-type="doi">10.1371/journal.pbio.3000327</pub-id>
<pub-id pub-id-type="pmid">31188823</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalfallah</surname><given-names>Y.</given-names></name><name><surname>Kuta</surname><given-names>R.</given-names></name><name><surname>Grasmuck</surname><given-names>C.</given-names></name><name><surname>Prat</surname><given-names>A.</given-names></name><name><surname>Durham</surname><given-names>H. D.</given-names></name><name><surname>Vande Velde</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>8</volume>:<issue>7551</issue>. <pub-id pub-id-type="doi">10.1038/s41598-018-25767-0</pub-id>
<pub-id pub-id-type="pmid">29765078</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kino</surname><given-names>Y.</given-names></name><name><surname>Washizu</surname><given-names>C.</given-names></name><name><surname>Kurosawa</surname><given-names>M.</given-names></name><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Miyazaki</surname><given-names>H.</given-names></name><name><surname>Akagi</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis.</article-title>
<source/><italic>Acta Neuropathol. Commun.</italic>
<volume>3</volume>:<issue>24</issue>. <pub-id pub-id-type="doi">10.1186/s40478-015-0202-6</pub-id>
<pub-id pub-id-type="pmid">25907258</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppers</surname><given-names>M.</given-names></name><name><surname>Blokhuis</surname><given-names>A. M.</given-names></name><name><surname>Westeneng</surname><given-names>H. J.</given-names></name><name><surname>Terpstra</surname><given-names>M. L.</given-names></name><name><surname>Zundel</surname><given-names>C. A.</given-names></name><name><surname>Vieira de Sa</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>78</volume>
<fpage>426</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24453</pub-id>
<pub-id pub-id-type="pmid">26044557</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwiatkowski</surname><given-names>T. J.</given-names><suffix>Jr.</suffix></name><name><surname>Bosco</surname><given-names>D. A.</given-names></name><name><surname>Leclerc</surname><given-names>A. L.</given-names></name><name><surname>Tamrazian</surname><given-names>E.</given-names></name><name><surname>Vanderburg</surname><given-names>C. R.</given-names></name><name><surname>Russ</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.</article-title>
<source/><italic>Science</italic>
<volume>323</volume>
<fpage>1205</fpage>–<lpage>1208</lpage>. <pub-id pub-id-type="doi">10.1126/science.1166066</pub-id>
<pub-id pub-id-type="pmid">19251627</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>E.</given-names></name><name><surname>Bui</surname><given-names>C. B.</given-names></name><name><surname>Shin</surname><given-names>W.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade.</article-title>
<source/><italic>EMBO Rep.</italic>
<volume>13</volume>
<fpage>150</fpage>–<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2011.246</pub-id>
<pub-id pub-id-type="pmid">22222206</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagier-Tourenne</surname><given-names>C.</given-names></name><name><surname>Polymenidou</surname><given-names>M.</given-names></name><name><surname>Cleveland</surname><given-names>D. W.</given-names></name></person-group> (<year>2010</year>). <article-title>TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>19</volume>
<fpage>R46</fpage>–<lpage>R64</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq137</pub-id>
<pub-id pub-id-type="pmid">20400460</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>R.</given-names></name><name><surname>Rohrer</surname><given-names>J. D.</given-names></name><name><surname>Real</surname><given-names>R.</given-names></name><name><surname>Lubbe</surname><given-names>S. J.</given-names></name><name><surname>Waite</surname><given-names>A. J.</given-names></name><name><surname>Blake</surname><given-names>D. J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders.</article-title>
<source/><italic>Cold Spring Harb. Mol. Case Stud.</italic>
<volume>5</volume>:<issue>a003913</issue>. <pub-id pub-id-type="doi">10.1101/mcs.a003913</pub-id>
<pub-id pub-id-type="pmid">31160356</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurin</surname><given-names>N.</given-names></name><name><surname>Brown</surname><given-names>J. P.</given-names></name><name><surname>Morissette</surname><given-names>J.</given-names></name><name><surname>Raymond</surname><given-names>V.</given-names></name></person-group> (<year>2002</year>). <article-title>Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.</article-title>
<source/><italic>Am. J. Hum. Genet.</italic>
<volume>70</volume>
<fpage>1582</fpage>–<lpage>1588</lpage>.<pub-id pub-id-type="pmid">11992264</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>7</volume>:<issue>12708</issue>. <pub-id pub-id-type="doi">10.1038/ncomms12708</pub-id>
<pub-id pub-id-type="pmid">27620379</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>S. C.</given-names></name><name><surname>Dastidar</surname><given-names>S. G.</given-names></name><name><surname>Tokunaga</surname><given-names>S.</given-names></name><name><surname>Ho</surname><given-names>W. Y.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name><name><surname>Ilieva</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis.</article-title>
<source/><italic>eLife</italic>
<volume>8</volume>:<issue>e40811</issue>. <pub-id pub-id-type="doi">10.7554/eLife.40811</pub-id>
<pub-id pub-id-type="pmid">30747709</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludtmann</surname><given-names>M. H.</given-names></name><name><surname>Arber</surname><given-names>C.</given-names></name><name><surname>Bartolome</surname><given-names>F.</given-names></name><name><surname>de Vicente</surname><given-names>M.</given-names></name><name><surname>Preza</surname><given-names>E.</given-names></name><name><surname>Carro</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Mutations in valosin-containing protein (VCP) decrease ADP/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>292</volume>
<fpage>8907</fpage>–<lpage>8917</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.762898</pub-id>
<pub-id pub-id-type="pmid">28360103</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>I. R.</given-names></name><name><surname>Rademakers</surname><given-names>R.</given-names></name><name><surname>Neumann</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.</article-title>
<source/><italic>Lancet Neurol.</italic>
<volume>9</volume>
<fpage>995</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70195-2</pub-id>
<pub-id pub-id-type="pmid">20864052</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>S.</given-names></name><name><surname>Hornburg</surname><given-names>D.</given-names></name><name><surname>Schludi</surname><given-names>M. H.</given-names></name><name><surname>Arzberger</surname><given-names>T.</given-names></name><name><surname>Rentzsch</surname><given-names>K.</given-names></name><name><surname>Schwenk</surname><given-names>B. M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>128</volume>
<fpage>485</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-014-1329-4</pub-id>
<pub-id pub-id-type="pmid">25120191</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>R. G.</given-names></name><name><surname>Mitchell</surname><given-names>J. D.</given-names></name><name><surname>Moore</surname><given-names>D. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).</article-title>
<source/><italic>Cochrane Database Syst. Rev.</italic>
<volume>3</volume>
<issue>CD001447</issue>.</mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>J.</given-names></name><name><surname>Guerrero</surname><given-names>E. N.</given-names></name><name><surname>Hegde</surname><given-names>P. M.</given-names></name><name><surname>Liachko</surname><given-names>N. F.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Vasquez</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>116</volume>
<fpage>4696</fpage>–<lpage>4705</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1818415116</pub-id>
<pub-id pub-id-type="pmid">30770445</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsui</surname><given-names>S.</given-names></name><name><surname>Otomo</surname><given-names>A.</given-names></name><name><surname>Nozaki</surname><given-names>M.</given-names></name><name><surname>Ono</surname><given-names>S.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Shirakawa</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model.</article-title>
<source/><italic>Mol. Brain</italic>
<volume>11</volume>:<issue>30</issue>. <pub-id pub-id-type="doi">10.1186/s13041-018-0373-8</pub-id>
<pub-id pub-id-type="pmid">29843805</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>S.</given-names></name><name><surname>Hesson</surname><given-names>L.</given-names></name><name><surname>Peggie</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma.</article-title>
<source/><italic>FEBS Lett.</italic>
<volume>582</volume>
<fpage>997</fpage>–<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2008.02.047</pub-id>
<pub-id pub-id-type="pmid">18307994</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>A. C.</given-names></name><name><surname>Dignon</surname><given-names>G. L.</given-names></name><name><surname>Kan</surname><given-names>Y.</given-names></name><name><surname>Zerze</surname><given-names>G. H.</given-names></name><name><surname>Parekh</surname><given-names>S. H.</given-names></name><name><surname>Mittal</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Molecular interactions underlying liquid-liquid phase separation of the FUS low-complexity domain.</article-title>
<source/><italic>Nat. Struct. Mol. Biol.</italic>
<volume>26</volume>
<fpage>637</fpage>–<lpage>648</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-019-0250-x</pub-id>
<pub-id pub-id-type="pmid">31270472</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalbandian</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>A. A.</given-names></name><name><surname>Srivastava</surname><given-names>R.</given-names></name><name><surname>Llewellyn</surname><given-names>K. J.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Shukr</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Activation of the NLRP3 inflammasome is associated with valosin-containing protein myopathy.</article-title>
<source/><italic>Inflammation</italic>
<volume>40</volume>
<fpage>21</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-016-0449-5</pub-id>
<pub-id pub-id-type="pmid">27730320</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M.</given-names></name><name><surname>Sampathu</surname><given-names>D. M.</given-names></name><name><surname>Kwong</surname><given-names>L. K.</given-names></name><name><surname>Truax</surname><given-names>A. C.</given-names></name><name><surname>Micsenyi</surname><given-names>M. C.</given-names></name><name><surname>Chou</surname><given-names>T. T.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</article-title>
<source/><italic>Science</italic>
<volume>314</volume>
<fpage>130</fpage>–<lpage>133</lpage>. <pub-id pub-id-type="pmid">17023659</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niaki</surname><given-names>A. G.</given-names></name><name><surname>Sarkar</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Rhine</surname><given-names>K.</given-names></name><name><surname>Vidaurre</surname><given-names>V.</given-names></name><name><surname>Guy</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-Linked FUS mutations.</article-title>
<source/><italic>Mol. Cell</italic>
<volume>77</volume>:<issue>82-94.e4</issue>. <pub-id pub-id-type="doi">10.1016/j.molcel.2019.09.022</pub-id>
<pub-id pub-id-type="pmid">31630970</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>T.</given-names></name><name><surname>Wilkinson</surname><given-names>A. J.</given-names></name></person-group> (<year>2001</year>). <article-title>AAA+ superfamily ATPases: common structure–diverse function.</article-title>
<source/><italic>Genes Cells</italic>
<volume>6</volume>
<fpage>575</fpage>–<lpage>597</lpage>. <pub-id pub-id-type="pmid">11473577</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Rourke</surname><given-names>J. G.</given-names></name><name><surname>Bogdanik</surname><given-names>L.</given-names></name><name><surname>Muhammad</surname><given-names>A. K.</given-names></name><name><surname>Gendron</surname><given-names>T. F.</given-names></name><name><surname>Kim</surname><given-names>K. J.</given-names></name><name><surname>Austin</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD.</article-title>
<source/><italic>Neuron</italic>
<volume>88</volume>
<fpage>892</fpage>–<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.10.027</pub-id>
<pub-id pub-id-type="pmid">26637796</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Zuber</surname><given-names>C.</given-names></name><name><surname>Roth</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Selective autophagy of cytosolic protein aggregates involves ribosome-free rough endoplasmic reticulum.</article-title>
<source/><italic>Histochem. Cell Biol.</italic>
<pub-id pub-id-type="doi">10.1007/s00418-019-01829-w</pub-id>
<comment>[Epub ahead of print]</comment>, <pub-id pub-id-type="pmid">31720797</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>F.</given-names></name><name><surname>Nguyen</surname><given-names>H. P.</given-names></name><name><surname>Van Mossevelde</surname><given-names>S.</given-names></name><name><surname>Moisse</surname><given-names>M.</given-names></name><name><surname>Sieben</surname><given-names>A.</given-names></name><name><surname>Santens</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients.</article-title>
<source/><italic>Neurobiol. Aging.</italic>
<volume>51</volume>
<fpage>e9</fpage>–<lpage>e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.12.008</pub-id>
<pub-id pub-id-type="pmid">28069311</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>A. K.</given-names></name><name><surname>Chow</surname><given-names>E. K.</given-names></name><name><surname>Goodnough</surname><given-names>J. B.</given-names></name><name><surname>Yeh</surname><given-names>W. C.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection.</article-title>
<source/><italic>J. Exp. Med.</italic>
<volume>199</volume>
<fpage>1651</fpage>–<lpage>1658</lpage>. <pub-id pub-id-type="pmid">15210743</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>O. M.</given-names></name><name><surname>Cabrera</surname><given-names>G. T.</given-names></name><name><surname>Tran</surname><given-names>H.</given-names></name><name><surname>Gendron</surname><given-names>T. F.</given-names></name><name><surname>McKeon</surname><given-names>J. E.</given-names></name><name><surname>Metterville</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Human C9ORF72 hexanucleotide expansion reproduces RNA Foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice.</article-title>
<source/><italic>Neuron</italic>
<volume>88</volume>
<fpage>902</fpage>–<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.018</pub-id>
<pub-id pub-id-type="pmid">26637797</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plewa</surname><given-names>J.</given-names></name><name><surname>Surampalli</surname><given-names>A.</given-names></name><name><surname>Wencel</surname><given-names>M.</given-names></name><name><surname>Milad</surname><given-names>M.</given-names></name><name><surname>Donkervoort</surname><given-names>S.</given-names></name><name><surname>Caiozzo</surname><given-names>V. J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene.</article-title>
<source/><italic>Neuromuscul. Disord.</italic>
<volume>28</volume>
<fpage>778</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1016/j.nmd.2018.06.007</pub-id>
<pub-id pub-id-type="pmid">30097247</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratnavalli</surname><given-names>E.</given-names></name><name><surname>Brayne</surname><given-names>C.</given-names></name><name><surname>Dawson</surname><given-names>K.</given-names></name><name><surname>Hodges</surname><given-names>J. R.</given-names></name></person-group> (<year>2002</year>). <article-title>The prevalence of frontotemporal dementia.</article-title>
<source/><italic>Neurology</italic>
<volume>58</volume>
<fpage>1615</fpage>–<lpage>1621</lpage>. <pub-id pub-id-type="pmid">12058088</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rea</surname><given-names>S. L.</given-names></name><name><surname>Walsh</surname><given-names>J. P.</given-names></name><name><surname>Layfield</surname><given-names>R.</given-names></name><name><surname>Ratajczak</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget’s disease of bone.</article-title>
<source/><italic>Endocr. Rev.</italic>
<volume>34</volume>
<fpage>501</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1210/er.2012-1034</pub-id>
<pub-id pub-id-type="pmid">23612225</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renton</surname><given-names>A. E.</given-names></name><name><surname>Majounie</surname><given-names>E.</given-names></name><name><surname>Waite</surname><given-names>A.</given-names></name><name><surname>Simon-Sanchez</surname><given-names>J.</given-names></name><name><surname>Rollinson</surname><given-names>S.</given-names></name><name><surname>Gibbs</surname><given-names>J. R.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.</article-title>
<source/><italic>Neuron</italic>
<volume>72</volume>
<fpage>257</fpage>–<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.09.010</pub-id>
<pub-id pub-id-type="pmid">21944779</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roczniak-Ferguson</surname><given-names>A.</given-names></name><name><surname>Ferguson</surname><given-names>S. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis.</article-title>
<source/><italic>bioRxiv [Preprint]</italic>
<pub-id pub-id-type="doi">10.26508/lsa.20190035</pub-id>
<pub-id pub-id-type="pmid">31527135</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothstein</surname><given-names>J. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Edaravone: a new drug approved for ALS.</article-title>
<source/><italic>Cell</italic>
<volume>171</volume>:<issue>725</issue>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.10.011</pub-id>
<pub-id pub-id-type="pmid">29100067</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryzhakov</surname><given-names>G.</given-names></name><name><surname>Randow</surname><given-names>F.</given-names></name></person-group> (<year>2007</year>). <article-title>SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK.</article-title>
<source/><italic>EMBO J.</italic>
<volume>26</volume>
<fpage>3180</fpage>–<lpage>3190</lpage>. <pub-id pub-id-type="pmid">17568778</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saracino</surname><given-names>D.</given-names></name><name><surname>Clot</surname><given-names>F.</given-names></name><name><surname>Camuzat</surname><given-names>A.</given-names></name><name><surname>Anquetil</surname><given-names>V.</given-names></name><name><surname>Hannequin</surname><given-names>D.</given-names></name><name><surname>Guyant-Marechal</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Novel VCP mutations expand the mutational spectrum of frontotemporal dementia.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>72</volume>
<fpage>e11</fpage>–<lpage>e14</lpage>.</mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scekic-Zahirovic</surname><given-names>J.</given-names></name><name><surname>Sendscheid</surname><given-names>O.</given-names></name><name><surname>El Oussini</surname><given-names>H.</given-names></name><name><surname>Jambeau</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Mersmann</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss.</article-title>
<source/><italic>EMBO J.</italic>
<volume>35</volume>
<fpage>1077</fpage>–<lpage>1097</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201592559</pub-id>
<pub-id pub-id-type="pmid">26951610</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>E. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1647</volume>
<fpage>65</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2016.03.036</pub-id>
<pub-id pub-id-type="pmid">27033831</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>Q.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>J. F.</given-names></name></person-group> (<year>2019</year>). <article-title>C9orf72 deficiency promotes motor deficits of a C9ALS/FTD mouse model in a dose-dependent manner.</article-title>
<source/><italic>Acta Neuropathol. Commun.</italic>
<volume>7</volume>:<issue>32</issue>.</mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Staats</surname><given-names>K. A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>W. H.</given-names></name><name><surname>Hung</surname><given-names>S. T.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>24</volume>
<fpage>313</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4490</pub-id>
<pub-id pub-id-type="pmid">29400714</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>P. R.</given-names></name><name><surname>Nieva</surname><given-names>G. V.</given-names></name><name><surname>Igaz</surname><given-names>L. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Suppression of conditional TDP-43 transgene expression differentially affects early cognitive and social phenotypes in TDP-43 Mice.</article-title>
<source/><italic>Front. Genet.</italic>
<volume>10</volume>:<issue>369</issue>. <pub-id pub-id-type="doi">10.3389/fgene.2019.00369</pub-id>
<pub-id pub-id-type="pmid">31068973</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreedharan</surname><given-names>J.</given-names></name><name><surname>Blair</surname><given-names>I. P.</given-names></name><name><surname>Tripathi</surname><given-names>V. B.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Vance</surname><given-names>C.</given-names></name><name><surname>Rogelj</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.</article-title>
<source/><italic>Science</italic>
<volume>319</volume>
<fpage>1668</fpage>–<lpage>1672</lpage>. <pub-id pub-id-type="doi">10.1126/science.1154584</pub-id>
<pub-id pub-id-type="pmid">18309045</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>M. J.</given-names></name><name><surname>Volkening</surname><given-names>K.</given-names></name><name><surname>Hammond</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Strong</surname><given-names>W.</given-names></name><name><surname>Leystra-Lantz</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.</article-title>
<source/><italic>Mol. Cell Neurosci.</italic>
<volume>35</volume>
<fpage>320</fpage>–<lpage>327</lpage>. <pub-id pub-id-type="pmid">17481916</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Polyubiquitin chain-induced p62 phase separation drives autophagic cargo segregation.</article-title>
<source/><italic>Cell Res.</italic>
<volume>28</volume>
<fpage>405</fpage>–<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-018-0017-7</pub-id>
<pub-id pub-id-type="pmid">29507397</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>R. H.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>W. S.</given-names></name><name><surname>Dobson-Stone</surname><given-names>C.</given-names></name><name><surname>Kwok</surname><given-names>J. B.</given-names></name><name><surname>Kiernan</surname><given-names>M. C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.</article-title>
<source/><italic>Acta Neuropathol. Commun.</italic>
<volume>5</volume>:<issue>76</issue>. <pub-id pub-id-type="doi">10.1186/s40478-017-0480-2</pub-id>
<pub-id pub-id-type="pmid">29078806</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>J. P.</given-names></name><name><surname>Brown</surname><given-names>R. H.</given-names><suffix>Jr.</suffix></name><name><surname>Cleveland</surname><given-names>D. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Decoding ALS: from genes to mechanism.</article-title>
<source/><italic>Nature</italic>
<volume>539</volume>
<fpage>197</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1038/nature20413</pub-id>
<pub-id pub-id-type="pmid">27830784</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teyssou</surname><given-names>E.</given-names></name><name><surname>Takeda</surname><given-names>T.</given-names></name><name><surname>Lebon</surname><given-names>V.</given-names></name><name><surname>Boillee</surname><given-names>S.</given-names></name><name><surname>Doukoure</surname><given-names>B.</given-names></name><name><surname>Bataillon</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>125</volume>
<fpage>511</fpage>–<lpage>522</lpage>.<pub-id pub-id-type="pmid">23417734</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>R. M.</given-names></name><name><surname>Boxer</surname><given-names>A. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Treatment of frontotemporal dementia.</article-title>
<source/><italic>Curr. Treat. Options Neurol.</italic>
<volume>16</volume>:<issue>319</issue>. <pub-id pub-id-type="doi">10.1007/s11940-014-0319-0</pub-id>
<pub-id pub-id-type="pmid">25238733</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twomey</surname><given-names>E. C.</given-names></name><name><surname>Ji</surname><given-names>Z.</given-names></name><name><surname>Wales</surname><given-names>T. E.</given-names></name><name><surname>Bodnar</surname><given-names>N. O.</given-names></name><name><surname>Ficarro</surname><given-names>S. B.</given-names></name><name><surname>Marto</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding.</article-title>
<source/><italic>Science</italic>
<volume>365</volume>:<issue>1033</issue>. <pub-id pub-id-type="doi">10.1126/science.aax1033</pub-id>
<pub-id pub-id-type="pmid">31249135</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M.</given-names></name><name><surname>Fagerberg</surname><given-names>L.</given-names></name><name><surname>Hallstrom</surname><given-names>B. M.</given-names></name><name><surname>Lindskog</surname><given-names>C.</given-names></name><name><surname>Oksvold</surname><given-names>P.</given-names></name><name><surname>Mardinoglu</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Proteomics. Tissue-based map of the human proteome.</article-title>
<source/><italic>Science</italic>
<volume>347</volume>:<issue>1260419</issue>. <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
<pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Langenhove</surname><given-names>T.</given-names></name><name><surname>van der Zee</surname><given-names>J.</given-names></name><name><surname>Sleegers</surname><given-names>K.</given-names></name><name><surname>Engelborghs</surname><given-names>S.</given-names></name><name><surname>Vandenberghe</surname><given-names>R.</given-names></name><name><surname>Gijselinck</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Genetic contribution of FUS to frontotemporal lobar degeneration.</article-title>
<source/><italic>Neurology</italic>
<volume>74</volume>
<fpage>366</fpage>–<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ccc732</pub-id>
<pub-id pub-id-type="pmid">20124201</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Mossevelde</surname><given-names>S.</given-names></name><name><surname>van der Zee</surname><given-names>J.</given-names></name><name><surname>Gijselinck</surname><given-names>I.</given-names></name><name><surname>Engelborghs</surname><given-names>S.</given-names></name><name><surname>Sieben</surname><given-names>A.</given-names></name><name><surname>Van Langenhove</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort.</article-title>
<source/><italic>Brain</italic>
<volume>139(Pt 2)</volume>, <fpage>452</fpage>–<lpage>467</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv358</pub-id>
<pub-id pub-id-type="pmid">26674655</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rheenen</surname><given-names>W.</given-names></name><name><surname>Shatunov</surname><given-names>A.</given-names></name><name><surname>Dekker</surname><given-names>A. M.</given-names></name><name><surname>McLaughlin</surname><given-names>R. L.</given-names></name><name><surname>Diekstra</surname><given-names>F. P.</given-names></name><name><surname>Pulit</surname><given-names>S. L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>48</volume>
<fpage>1043</fpage>–<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3622</pub-id>
<pub-id pub-id-type="pmid">27455348</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>C.</given-names></name><name><surname>Rogelj</surname><given-names>B.</given-names></name><name><surname>Hortobagyi</surname><given-names>T.</given-names></name><name><surname>De Vos</surname><given-names>K. J.</given-names></name><name><surname>Nishimura</surname><given-names>A. L.</given-names></name><name><surname>Sreedharan</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.</article-title>
<source/><italic>Science</italic>
<volume>323</volume>
<fpage>1208</fpage>–<lpage>1211</lpage>. <pub-id pub-id-type="doi">10.1126/science.1165942</pub-id>
<pub-id pub-id-type="pmid">19251628</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model.</article-title>
<source/><italic>Glia</italic>
<volume>59</volume>
<fpage>946</fpage>–<lpage>958</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21167</pub-id>
<pub-id pub-id-type="pmid">21446050</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>G. D.</given-names></name><name><surname>Wymer</surname><given-names>J.</given-names></name><name><surname>Kovach</surname><given-names>M. J.</given-names></name><name><surname>Mehta</surname><given-names>S. G.</given-names></name><name><surname>Mumm</surname><given-names>S.</given-names></name><name><surname>Darvish</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>36</volume>
<fpage>377</fpage>–<lpage>381</lpage>. <pub-id pub-id-type="pmid">15034582</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidberg</surname><given-names>H.</given-names></name><name><surname>Elazar</surname><given-names>Z.</given-names></name></person-group> (<year>2011</year>). <article-title>TBK1 mediates crosstalk between the innate immune response and autophagy.</article-title>
<source/><italic>Sci. Signal.</italic>
<volume>4</volume>:<issue>e39</issue>. <pub-id pub-id-type="doi">10.1126/scisignal.2002355</pub-id>
<pub-id pub-id-type="pmid">21868362</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreich</surname><given-names>M.</given-names></name><name><surname>Shepheard</surname><given-names>S. R.</given-names></name><name><surname>Verber</surname><given-names>N.</given-names></name><name><surname>Wyles</surname><given-names>M.</given-names></name><name><surname>Heath</surname><given-names>P. R.</given-names></name><name><surname>Highley</surname><given-names>J. R.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis.</article-title>
<source/><italic>Neuropathol. Appl. Neurobiol.</italic>
<pub-id pub-id-type="doi">10.1111/nan.12578</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">31498468</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weishaupt</surname><given-names>J. H.</given-names></name><name><surname>Hyman</surname><given-names>T.</given-names></name><name><surname>Dikic</surname><given-names>I.</given-names></name></person-group> (<year>2016</year>). <article-title>Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia.</article-title>
<source/><italic>Trends Mol. Med.</italic>
<volume>22</volume>
<fpage>769</fpage>–<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2016.07.005</pub-id>
<pub-id pub-id-type="pmid">27498188</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>M. A.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Duffy</surname><given-names>A.</given-names></name><name><surname>Adalbert</surname><given-names>R.</given-names></name><name><surname>Phillips</surname><given-names>B. U.</given-names></name><name><surname>Peters</surname><given-names>O. M.</given-names></name><etal></etal></person-group> (<year>2018a</year>). <article-title>Publisher Correction: TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>21</volume>:<issue>1138</issue>. <pub-id pub-id-type="doi">10.1038/s41593-018-0160-y</pub-id>
<pub-id pub-id-type="pmid">29872124</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>M. A.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Duffy</surname><given-names>A.</given-names></name><name><surname>Adalbert</surname><given-names>R.</given-names></name><name><surname>Phillips</surname><given-names>B. U.</given-names></name><name><surname>Peters</surname><given-names>O. M.</given-names></name><etal></etal></person-group> (<year>2018b</year>). <article-title>TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>21</volume>
<fpage>552</fpage>–<lpage>563</lpage>.<pub-id pub-id-type="pmid">29556029</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Shu</surname><given-names>X.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Loss of mitochondrial protein CHCHD10 in skeletal muscle causes neuromuscular junction impairment.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<pub-id pub-id-type="doi">10.1093/hmg/ddz154</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">31261376</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Willis</surname><given-names>T. L.</given-names></name><name><surname>Button</surname><given-names>R. W.</given-names></name><name><surname>Strang</surname><given-names>C. J.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Cytoplasmic DAXX drives SQSTM1/p62 phase condensation to activate Nrf2-mediated stress response.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>10</volume>:<issue>3759</issue>. <pub-id pub-id-type="doi">10.1038/s41467-019-11671-2</pub-id>
<pub-id pub-id-type="pmid">31434890</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffagnini</surname><given-names>G.</given-names></name><name><surname>Savova</surname><given-names>A.</given-names></name><name><surname>Danieli</surname><given-names>A.</given-names></name><name><surname>Romanov</surname><given-names>J.</given-names></name><name><surname>Tremel</surname><given-names>S.</given-names></name><name><surname>Ebner</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Phasing out the bad-How SQSTM1/p62 sequesters ubiquitinated proteins for degradation by autophagy.</article-title>
<source/><italic>Autophagy</italic>
<volume>14</volume>
<fpage>1280</fpage>–<lpage>1282</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2018.1462079</pub-id>
<pub-id pub-id-type="pmid">29929426</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Donnelly</surname><given-names>C. J.</given-names></name><name><surname>Haeusler</surname><given-names>A. R.</given-names></name><name><surname>Grima</surname><given-names>J. C.</given-names></name><name><surname>Machamer</surname><given-names>J. B.</given-names></name><name><surname>Steinwald</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.</article-title>
<source/><italic>Nature</italic>
<volume>525</volume>
<fpage>56</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1038/nature14973</pub-id>
<pub-id pub-id-type="pmid">26308891</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. J.</given-names></name><name><surname>Gendron</surname><given-names>T. F.</given-names></name><name><surname>Ebbert</surname><given-names>M. T. W.</given-names></name><name><surname>O’Raw</surname><given-names>A. D.</given-names></name><name><surname>Yue</surname><given-names>M.</given-names></name><name><surname>Jansen-West</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>24</volume>
<fpage>1136</fpage>–<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0071-1</pub-id>
<pub-id pub-id-type="pmid">29942091</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z. D.</given-names></name><name><surname>Saw</surname><given-names>W. T.</given-names></name><name><surname>Tan</surname><given-names>E. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Mitochondrial CHCHD-containing proteins: physiologic functions and link with neurodegenerative diseases.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<volume>54</volume>
<fpage>5534</fpage>–<lpage>5546</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0099-5</pub-id>
<pub-id pub-id-type="pmid">27631878</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>